Drug Type Antibody toxin conjugate |
Synonyms Anti-CD5 monoclonal antibody-ricin-chain-A conjugate, Anti-CD5 ricin A chain immunotoxin, Muromonab + [6] |
Target |
Action inhibitors |
Mechanism T-cell surface glycoprotein CD5 inhibitors, Immunosuppressants |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06381 | Zolimomab aritox | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Graft vs Host Disease | Phase 3 | United States | - | - |
Graft vs Host Disease | Phase 3 | - | - | |
Graft vs Host Disease | Phase 3 | - | - | |
Graft vs Host Disease | Phase 3 | - | - | |
Diabetes Mellitus | Phase 2 | United States | - | - |
Diabetes Mellitus | Phase 2 | - | - | |
Diabetes Mellitus | Phase 2 | - | - | |
Diabetes Mellitus | Phase 2 | - | - | |
Renal transplant rejection | Phase 2 | - | - | |
Renal transplant rejection | Phase 2 | - | - |